Sign In
Buy EW
$86.00
-1.66 (-1.89%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs
12:00am, Friday, 24'th Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 23)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Acceleron Pharma Inc (NASDAQ: XLRN)
Aerpio...
Edwards Lifesciences' (EW) CEO Mike Mussallem on Q2 2020 Results - Earnings Call Transcript
11:14pm, Thursday, 23'rd Jul 2020
Edwards Lifesciences Corp. (NYSE:EW) Q2 2020 Earnings Conference Call July 23, 2020 5:00 PM ET Company Participants Mark Wilterding – Vice President-Investor Relations Mike Mussallem – Chairman an
Edwards Lifesciences (EW) Q2 Earnings and Revenues Beat Estimates
09:35pm, Thursday, 23'rd Jul 2020
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 126.67% and 18.15%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Edwards Lifesciences: Q2 Earnings Insights
08:49pm, Thursday, 23'rd Jul 2020
Shares of Edwards Lifesciences (NYSE:EW) moved higher by 3.5% in after-market trading after the company reported Q2 results.Quarterly Results Earnings per share decreased 75.36% year over year to $0.3
Edwards Lifesciences Stares Down A Buy Point After Its Earnings Beat
08:37pm, Thursday, 23'rd Jul 2020
Late Thursday, Edwards Lifesciences reported adjusted income of 34 cents per share on $925 million in sales for its second quarter ended June 30. In response, EW stock popped.
Edwards Lifesciences Reports Second Quarter Results
08:15pm, Thursday, 23'rd Jul 2020
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarte
The Daily Biotech Pulse: Midatech Shelves Sale Plan, G1 Therapeutics Out-Licenses, Entera Bio Jumps On Survey Results
12:00am, Thursday, 23'rd Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)
ABIOMED, Inc. (NASDAQ: ABMD)
Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO)
Bio-Rad Laboratories,...
If You Own Edwards Lifesciences (EW) Stock, Should You Sell It Now?
05:04pm, Wednesday, 22'nd Jul 2020
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Large-Cap Growth Fund posted a return of 27.86% for the quarter, outperforming its benchmark, t
Why Earnings Season Could Be Great for Edwards Lifesciences (EW)
12:39pm, Wednesday, 22'nd Jul 2020
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Abbott Labs Leveraging An Opportunity In Diagnostics While Looking Forward To Normalization
03:43pm, Tuesday, 21'st Jul 2020
Abbott posted a good second quarter, with the expected outperformance in diagnostics, but also better results in devices, diabetes, and nutrition.
Is Edwards Lifesciences Corporation's(NYSE:EW) Recent Stock Performance Tethered To Its Strong Fundamentals?
04:36pm, Monday, 20'th Jul 2020
Most readers would already be aware that Edwards Lifesciences' (NYSE:EW) stock increased significantly by 9.3% over...
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
04:31pm, Thursday, 16'th Jul 2020
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences (EW) in Q2 Earnings?
01:36pm, Thursday, 16'th Jul 2020
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Paul LaViolette Appointed To Edwards Lifesciences Board Of Directors
12:30pm, Wednesday, 15'th Jul 2020
Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Paul A. LaViolette has bee
Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients
12:00am, Wednesday, 15'th Jul 2020
Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces in
